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Background/aim: We aimed to identify clinical settings of renal transplant patients with COVID-19.
Materials and methods: In this retrospective study, we included kidney transplant inpatients with laboratory confirmed COVID-19
who had been discharged or had died by October 1st, 2020. Characteristics of the patients, including basal and last outpatient
biochemical parameters were recorded. Discontinuation or dosage reduction of immunosuppressives and other treatment information
was documented.
Results: Twenty patients were included in this study, of whom 18 were discharged and 2 died in hospital. The mean duration of
hospitalization and follow-up were 9.7 ± 6.4 days and 4.5 ± 2.0 months, respectively. Fourteen patients (70%) were male and mean
age was 48.0 ± 10.3 years. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/
day (50%) or dexamethasone (50%). Tacrolimus/m-TOR inhibitors were reduced by 50% and all antimetabolites were discontinued.
Hemodialysis was needed for 10% of patients. Acute kidney injury was detected in 25% of the patients. With respect to hospitalization
time and complications, there was no significant difference between patients who used dexamethasone and those who did not (P >
0.05). The discontinued immunosuppressives were resumed within 2 to 4 weeks after discharge according to the severity of disease. No
rehospitalization or acute rejection was detected during the follow-up of the patients.
Conclusion: Renal transplant patients are considered a high risk group for COVID-19. It can be said that discontinuation or reducing
dosages of immunosuppressives may be effective and safe in kidney transplant patients.
Key words: COVID-19, SARS-CoV-2, kidney transplantation, immunosuppression, mortality, acute rejection

1. Introduction
The new coronavirus (COVID-19) outbreak is the worst
disaster for humanity in the twenty-first century. The
COVID-19 pandemic, caused by SARS-CoV-2 virus,
has infected approximately forty two million people
worldwide, and continues to pose a serious public health
threat. COVID-19 disease may have a more fatal course
when accompanied by certain comorbid conditions such
as advanced age, diabetes mellitus, hypertension, heart
disease, and solid organ transplantation [1]. Although
renal transplant patients may have symptoms such as
fever, cough, and shortness of breath, which are the most

common symptoms observed during the course of the
pandemic in the normal population, they may also have
a broad range of atypical symptoms, such as fever and
diarrhea without respiratory symptoms [2,3].
Short-term mortality rates due to SARS-CoV-2
pneumonia in patients with solid organ transplants
are reported to be quite high compared to the normal
population [4,5]. However, COVID-19 related mortality
rates have been reported as 0%–41.3% and vary from
country to country [6]. In addition, the populations
of the reported studies in the literature were mostly
cadaveric kidney recipients. Given their diminished T
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cell immunity, transplant recipients are expected to be
at higher risk for severe bacterial and viral infections.
Expected clinical course and mortality risk rates are higher
in patients with renal transplants, due to administration
of maintenance immunosuppressive agents and having
comorbid conditions, compared to those of the normal
population. So far, different approaches proposed for
the renal transplant patients with COVID-19 include
stopping antimetabolites and/or stopping or reducing the
dose of calcineurin inhibitors (CNI) and increasing the
dose of maintenance steroids [7,8]. However, although
there is no clear evidence, some authors have suggested
that CNIs may be used for therapeutic purposes for
COVID-19 and there is no need for discontinuation in
patients with renal transplants [9]. In addition to these
treatment options, dexamethasone, hydroxychloroquine,
remdesivir, favipiravir, lopinavir/ritonavir, tocilizumab,
and convalescent plasma have also been reported as
treatment options, although their exact effects still remain
controversial [10–12]. However, while discontinuation
of immunosuppressive therapy in these patients has an
advantage in slowing the disease progression, there is
a possibility that subclinical or clinical acute rejection
attacks may occur by reactivating the immune system. In
addition, there is no clear consensus yet regarding when
discontinued or reduced immunosuppressive agents can
be resumed.
The aim of this study is to describe the clinical features
of kidney transplant patients with COVID-19 at the time
of diagnosis and to investigate the patients and graft
survival after treatment.
2. Methods
2.1. Study design and patients
This descriptive crosssectional study included 20 renal
transplant patients treated for COVID-19 between March
20 and October 1, 2020. Demographic characteristics of the
patients were recorded, including age, sex, body mass index,
type and time of transplantation, immunosuppressive drugs
used, presence of comorbid conditions, and the form of
radiological involvement. The patient’s history of induction
therapy, acute rejection therapy, and whether they had a
viral infection were also documented. Symptoms, duration
of complaint before admission, average hospitalization
time, transition to the intensive care unit, or time of death
were other parameters of interest. Baseline biochemical
parameters and other items, including graft function
tests, liver function tests, whole blood count, D-dimer,
ferritin, lactate dehydrogenase (LDH), C-reactive protein
(CRP), fibrinogen, prothrombin time, activated partial
thromboplastin time, thoracic computed tomography
(CT), and nasopharyngeal COVID-19 reversetranscription polymerase chain reaction (RT-PCR) tests

were used to determine the prognosis of the patients. RTPCR tests were repeated within the first 24 h in patients
with a negative first RT-PCR.
2.2. Modification of immunosuppressive protocol
To control further progression of the underlying disease
as well as for treatment purposes, antimetabolites were
halted and CNI dose was reduced by 50% in patients
with mild-to-moderate pneumonia (target CNI serum
levels 4–6 µg/mL); receiving steroid/antimetabolite/CNI.
If the patient was receiving steroid/CNI/mammalian
or mechanistic target of rapamycin inhibitor (mTORi),
it was planned to reduce the doses of both CNI and
M-TORi by 50% (CNI level: 2–3, m-TORi level: 2–3
µg/mL). According to the severity of disease, it was
planned to discontinue immunosuppressants, except for
increasing methylprednisolone (16 mg/day) or switching
to dexamethasone (6 mg/day) for 10 days.
2.3. Statistical analysis
Data analysis was performed by using SPSS-22 for
Windows (SPSS Inc. Chicago IL, USA®Z). The variables
were investigated using visual (histograms, probability
plot) and analytical methods (Shapiro–Wilk’s test) to
determine whether or not they are normally distributed.
We performed analyses to describe and summarize the
distributions of variables. The continuous variables were
expressed as mean and standard deviation or as median
and interquartile range, depending on the normality of
their distribution. The Mann–Whitney test was used to
compare the variables that were not normally distributed.
On the other hand, Student’s t-test was used to compare
the variables with normal distribution. In two different
periods of the disease, the Wilcoxon test was preferred to
compare nonparametric variables, while paired Student’s
t-test was used for variables with normal distribution. To
compare the qualitative data, the chi-square test or Fisher’s
exact test (when chi-square test assumptions do not hold
due to low expected cell counts) was used. A P-value of <
0.05 was accepted as statistically significant.
3. Results
3.1. General characteristics
The study was carried out upon receiving the approval
of the Ethics Committee of Sakarya University Faculty
of Medicine (no.: 71522473/050.01.04/208 and dated
20.04.2020). Of the 380 renal transplant patients followed
up at our center, 20 renal transplant patients were diagnosed
with SARS-CoV-2. All the patients were hospitalized for
treatment and follow-up. The most frequently detected
blood group was blood group A with 45% amongst the
patients. This was followed by blood group O with 30%,
and blood group B with 25%. None of the patients had
AB blood group type. Two patients (10%) died while the
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graft was functional because of acute respiratory distress
syndrome due to severe COVID-19 pneumonia. After
COVID-19 treatment, two patients had stage-5 chronic
renal failure (CRF) and the patients were discharged to be
treated with chronic hemodialysis (HD). The remaining
16 (80%) patients were discharged from the hospital after
a full recovery.
3.2. Clinical findings and hospitalization outcomes
The mean duration of hospitalization and follow-up were
9.7 ± 6.4 days and 4.5 ± 2.0 months, respectively. Of the
patients, 14 (70%) were male and the mean age was 48.0
± 10.3 (30–64) years. Median dialysis duration (IQR)
before transplantation was 12.0 (3.75–45.75) months,
and the mean time (± SD) from kidney transplantation
to onset of COVID-19 infection was 71.9 ± 52.7 months.
Prevalent comorbidities included hypertension (60%),
chronic allograft dysfunction (15%), diabetes mellitus
(25%), and chronic heart disease (15%). Their symptoms
started at a median of 2 days (1–5 days) before admission
to the hospital. The other demographic and biochemical
parameters of the patients are summarized in Table 1. The
most common symptoms were fever (75%), cough (75%),
shortness of breath (50%), and myalgia (50%), whereas
sore throat (15%) and diarrhea (5%) were less common.
All patients were treated with anti-T-lymphocyte globulin
(ATG) as induction therapy. Two patients were treated in
the intensive care unit and the rest of the patients were
treated in the ward. Of the patients, 85% had a history of
living, and 15% deceased renal transplantation. In terms
of complications developed during the treatment process,
acute renal failure in 5 (25%) patients, sepsis in 2 (10%)
patients, requirement for mechanical ventilation support
in 2 (10%) patients, and a chronic hemodialysis program
were required in 2 patients. Two patients who were
included in the hemodialysis program were being followed
up because they had stage 4 chronic kidney damage. Two
(10%) patients died during the follow-up period (Figure).
The abnormal parameters detected at admission were
significantly improved in the outpatient controls. During
follow-up, no rehospitalization, acute graft dysfunction
or acute rejection was detected in any of the patients. The
mean resuming time of antimetabolites and CNIs was 2.0
(2.0–3.0) weeks. We resumed immunosuppressives after 2
weeks for patients with mild symptoms, and after 4 weeks
for the patients with moderate or severe radiological
involvement.
3.3. Laboratory results
We identified RT-PCR positivity in all (100%) cases. Of
these patients, 23% was confirmed to be positive with
the second nasopharyngeal swab. Sixteen patients (90%)
had bilateral typical COVID-19–associated radiological
findings. The laboratory findings reported at the time of
the diagnosis of COVID-19 infection were compared with
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Table 1. Demographic and baseline characteristics of kidney
transplant recipients with a diagnosis of COVID-19.
Results

Items

(n = 20)

Age (years), mean values ±
SD (min–max.)
Sex (F/M), n (%)

48.0 ± 10.3 (30–64)
5/14 (30/70)

Body mass index (BMI, kg/m2) 25.5 ± 2.7
Blood groups, n (%)

A
B
O
AB

Comorbid condition
Hypertension
Diabetes mellitus
Chronic heart disease
Chronic allograft dysfunction
Duration of dialysis prior
transplantation (months),
(IQR)
Transplant duration (months),
mean values ± SD
Mean time of hospitalization
(days), mean ± SD
Transplant type (%)
Living (%)
Deceased (%)
Bilateral/unilateral/normal
chest CT findings (%)
Change in
immunosuppression, n (%)
Discontinued antimetabolite
only
Discontinued antimetabolite
and CNI/m-TORi
Increased steroid dose
Supporting/antiviral treatment,
n (%)
Favipiravir
Hydroxychloroquine
Dexamethasone
Oseltamivire
Convalescent plasma
Antibacterial antibiotics
Restarting time of
immunosuppression, weeks
Duration of follow-up, months,
mean values ± SD

9 (45)
5 (25)
6 (30)
12 (60)
5 (25)
3 (15)
3 (15)
12.0 (3.75–45.75)
71.9 ± 52.7 (7.2–157.8)
9.7 ± 6.4 (0–23)
17 (85)
3 (15)
15/3/2 (75/15 /10)

20 (100)
7 (35)
17 (85)

18 (90)
10 (50)
10 (50)
9 (45)
6 (30)
13 (65)
2.0 (2.0–3.0)
4.5 ± 2.0 (0.7–6.5)

DHEİR et al. / Turk J Med Sci
0%
15%

AKI
Mecanic ventilation

39%

Sepsis

15%

Dialysis requirement
Died
Acute rejection

15%
16%

Figure. Frequency of complications during the follow-up of kidney transplant
patients diagnosed with COVID-19.

Table 2. Laboratory findings and comparison before and after COVID-19 infection treatment.
Laboratory findings
Variables

Outcomes at admission no = 16

Outcomes at outpatient no = 16

P-value

5.67 ± 2.77

7.88 ± 2.10

0.030

Absolute lymphocyte count, 10 /mm

1.22 ± 0.52

2.37 ± 1.37

0.319

Neutrophil to lymphocyte ratio

3.34 ± 1.96

2.75 ± 2.05

0.397

Platelet count, 10 /mm

211 ± 69

220 ± 87

0.006

White blood cell count, 10 /mm
3

3

3

3

3

Serum creatinine, mg/dL
C-reactive protein (CRP), mg/L
Procalcitonin, ng/mL

3

1.15 (0.93–1.83)

1.13 (0.85–1.84)

31 (20–58)

4.3 (3.0–18.2)

0.076 (0.031–0.48)

0.025 (0.1–0.03)

0.897
0.001
0.020

Alanine aminotransaminase, IU/L

25 (18–33)

18 (15–27)

0.036

Fibrinogen, mg/dL

449 ± 123

290 ± 77

0.570

2 32 (180–320)

0.173

D-dimer, ng/mL

325 (216–706)

Albumin, g/L

3.55 (3.3–4.17)

Ferritin, ng/mL

221 (102–795)

those of the last outpatient control date. The median (IQR)
values of basal serum creatinine was 1.15 mg/dL (0.93–
1.83) and 1.13 (0.85–1.84) at the end of follow-up (P =
0.897). Similarly, a significant improvement was detected
in white blood cell count (WBC) (P = 0.030), CRP (P
= 0.001), alanine aminotransferase (P = 0.036), serum
albumin (P = 0.018), and ferritin (P = 0.018) levels (Table
2). No treatment-related QT prolongation was detected
in any of the patients. According to hospitalization
time, complications like AKI, sepsis, needing mechanic
ventilator, and mortality, there was no significant difference

4.25 (3.6–4.6)
47 (20–136)

0.018
0.001

between the patients who used dexamethasone and those
who did not (P > 0.05) (Table 3).
3.4. Imaging results
According to thoracic CT findings, 15 patients (75%) had
bilateral and 3 (15%) had unilateral lung involvement,
whereas two patients (10%) with nasopharyngeal swab
RT-PCR positivity had normal radiological findings. There
were ground-glass opacities in 18 cases (90%), groundglass combined with consolidation in 8 cases (40%), and
bilateral pleural effusions combined with ground-glass
image in 5 cases (25%).
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Table 3. Comparison of complications developed according to dexamethasone treatment.

AKI
Sepsis
Need for hemodialysis
Mechanical ventilator requirement
Mortality
Hospitalization (day)

No

Using dexamethasone
no = 10
8 (80%)

Not using dexamethasone
no = 10
7 (70%)

Yes

2 (20%)

3 (30%)

No

8 (100%)

8 (80%)

Yes

0 (0%)

2 (20%)

No

9 (90%)

9 (90%)

Yes

1 (10%)

1 (10%)

No

10 (100%)

8 (80%)

Yes

0 (0%)

2 (20%)

Deceased

1 (10%)

1 (10%)

Alive

9 (90%)

9 (90%)

5.5 (5–13)

9.5 (5–13)

3.5. Treatment protocols
Of the patients, 100% received 5 mg of maintenance
prednisolone, 90% tacrolimus, 35% everolimus, and 85%
was receiving mycophenolate mofetil (MMF). According
to severity of the disease, prednisolone dosage was
increased (16 mg/day) or started dexamethasone (6 mg/
day) for 10 days, tacrolimus/mTORi dose was withdrawal
or reduced by 50% and antimetabolites were discontinued
in all patients. In addition, simultaneously favipiravir
(90%), dexamethasone (50%), hydroxychloroquine (50%),
oseltamivir (45%), and convalescent plasma (30%) were
administered to the patients. Upon intense vomiting
complaints in addition to fever in one patient, cranial MRI
showed signs of temporal encephalitis. In this patient,
everolimus treatment was discontinued, and prednisolone
20 mg/day and favipiravir treatment was started. Herpes
meningitis was ruled out by taking a sample from
cerebrospinal fluid. After a decrease in complaints and a
full recovery, the patient was discharged.
Tacrolimus itself is rarely known to prolong QT [13].
No QT prolongation has developed in any of the patients
using hydroxychloroquine and tacrolimus.
3. Discussion
In our study, we evaluated the clinical course, treatment
approaches, and graft functions of kidney transplant
patients with COVID-19 disease during the mid-term
follow-up. During the COVID-19 pandemic, it is not easy
to determine the appropriate treatment strategy in terms
of patient and graft survival of transplant patients infected
with SARS-CoV-2. Supportive care remains the mainstay
of treatment for COVID-19, and there are currently no
antiviral therapies with proven efficacy. Maintenance
or increasing the dosage of steroid, withdrawal of
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P-value
0.606
0.477
1
0.474
0.702
0.673

antimetabolites, and reduction of the dosage of CNIs
was considered in patients with COVID-19 [5,9–12]. In
our study, we increased methylprednisolone or started
dexamethasone therapy for all patients depending on the
severity of the disease. Simultaneously, we also increased
the dose of tacrolimus and resumed antimetabolites on the
4th week for the mild-severe cases and after 2 weeks in
patients with mild-moderate findings. During the followup period we did not observe any acute rejection attacks
after halting MMF and decreasing the dose of tacrolimus/
m-TORi. However, discontinuation of immunosuppressive
agents could hypothetically exacerbate inflammation in
the absence of antiinflammatory agents. To our knowledge,
acute rejection attacks were reported in patients diagnosed
with COVID-19 in only one published case series [14].
Since hydroxychloroquine treatment was recommended
at the beginning of the pandemic, half of our patients
were treated with hydroxychloroquine. However,
recently, it has been proven by observational study
that hydroxychloroquine treatment is not effective for
treatment or prophylaxis of COVID-19 disease [15]. One
of the interesting antivirals suggested for COVID-19
treatment is favipiravir. It is recommended for patients
with COVID-19, based on data suggesting efficacy against
non-COVID-19 diseases [16]. Favipiravir has been shown
to demonstrate a more efficient and rapid viral clearance
in COVID-19 patients when compared to other antivirals
[17]. However, there is no evidence-based randomized
controlled study on the anti-COVID-19 efficacy of
favipiravir. Another effective agent in the treatment of
COVID-19 is dexamethasone, which has been proven to
significantly reduce 28-day COVID-19-related mortality
in the normal population [11]. In our study, we used
dexamethasone treatment in transplant patients with
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moderate to severe disease severity. However, with respect
to hospitalization time, complications and mortality, there
was no significant difference between the patients who
used dexamethasone and those who did not.
Of the patients, 90% were discharged from the hospital
after a short period of hospitalization. One of two patients
who died was a 64-year-old male patient who had a history
of multiple comorbid conditions (diabetes, coronary
artery disease, and peripheral artery disease, chronic graft
dysfunction, and hypertension). He died from severe
acute respiratory distress syndrome. The other patient
who died had only hypertension comorbid status and died
on the 16th day of admission. Thus, our mortality rate
was as low as 10%. In a similar study of 10 cases (average
age of 45 years), the mortality rate was reported as 10%
[18]. In one study [5], however, intubation and mortality
rates in transplant patients were as high as 39% and 28%,
respectively, after 3 weeks of follow-up. The main reason
for high mortality in this study may be the fact that the
population was older (average age was 60 years), 75% had
deceased transplant, and high ratio of comorbidities. In
addition, two patients who were followed at home with
mild symptoms died at home. Similarly, in a study of 20
renal transplant patients in Italy, COVID-19–associated
7-day mortality and intensive care unit hospitalization
rates were found as 25% and 20%, respectively [19].
Publications of similar series are reviewed and summarized
in Table 3. The mortality reported in the literature was
higher than our findings [5,20,21]. There could be various
explanations for that: most patients being transplanted
from a cadaver, being older, having multiple comorbidities,
or newly transplanted cases that eventually led to higher
exposure to immunosuppression. However, our patients
were transplanted from a living donor in 85% of the cases
and the duration of developing COVID infection from the
time of transplant was 71.9 ± 52.7 months. Therefore, we
had lower comorbidity rates than other reported studies,
where the baseline tacrolimus levels were below 6 ng/mL
and the patients were younger.
When we evaluated the common results of similar
studies, factors such as advanced age, hypertension, and
diabetes mellitus in transplant patients were found to be
associated with high mortality rates. This suggests that
stopping the antimetabolites and reducing the dose of CNI
agents from the beginning may be useful in these patients.
However, factors such as duration of transplantation, type
of transplantation, acute rejection history, emergence
of donor specific antibodies, advanced age, graft
dysfunction, degree of radiological involvement of the
lung, presence of sepsis, and comorbid conditions should
be considered before deciding to discontinue or reduce
immunosuppressive doses in these patients.

It has been shown that D-dimer level of >1 mg/mL
elevation is a poor prognostic indicator of COVID-19
disease in the normal population [22]. However, in a
multicenter study, no significant relationship was found
between elevated D-dimer and mortality in kidney
transplant COVID-19 patients [21]. We did not find
a significant difference with respect to D-dimer levels
between admission and outpatient in our patients. It
may be due to the fact that our patient population
has less comorbid conditions, received living kidney
transplantation, and used steroid therapy.
Procalcitonin is a peptide released in the setting of
systemic inflammation, in particular bacterial infections,
and the magnitude of elevation has correlated with
infection severity. Normally, procalcitonin is undetectable
in the circulation. With the recognition that procalcitonin
is a marker for severe infection, and has potential to
differentiate bacterial infections from viral infections [23].
Especially in patients with severe COVID-19, a positive
correlation was detected between elevated cytokines and
procalcitonin levels [24]. In the follow-up of our patients,
the progression of procalcitonin levels was detected in
65% of patients, and antibacterial treatment of the patients
was initiated.
The present study has several limitations. The small
sample size was the major limitation of our study.
In conclusion, kidney transplant recipients may be at
high risk of developing critical COVID-19 illness due to
chronic immunosuppression and comorbidities. In our
study, COVID-19–associated mortality rate was lower
than those in other published studies. The main reason of
this outcome may be the characteristics of our population
which was different from these studies. We did not
observe any acute rejection findings after halting MMF
and decreasing the dosage of tacrolimus. For restarting
immunosuppressives in these patients, resuming
antimetabolites, and increasing the dose of CNIs on the
4th week for the mid-severe cases, and after 2 weeks in
patients with mild-moderate findings may be a preferable
treatment approach.
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